Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Toll-like receptor (TLR) agonists can trigger broad inflammatory responses that elicit rapid innate immunity and promote the activities of lymphocytes, which can potentially enhance adoptive immunotherapy in the tumor-bearing setting. In the present study, we found that Polyinosinic:Polycytidylic Acid [Poly(I:C)] and CpG oligodeoxynucleotide 1826 [CpG], agonists for TLR 3 and 9, respectively, potently activated adoptively transferred T cells against a murine model of established melanoma. Intratumoral injection of Poly(I:C) and CpG, combined with systemic transfer of activated pmel-1 T cells, specific for gp10025–33, led to enhanced survival and eradication of 9-day established subcutaneous B16F10 melanomas in a proportion of mice. A series of survival studies in knockout mice supported a key mechanistic pathway, whereby TLR agonists acted via host cells to enhance IFN-γ production by adoptively transferred T cells. IFN-γ, in turn, enhanced the immunogenicity of the B16F10 melanoma line, leading to increased killing by adoptively transferred T cells. Thus, this combination approach counteracted tumor escape from immunotherapy via downregulation of immunogenicity. In conclusion, TLR agonists may represent advanced adjuvants within the setting of adoptive T-cell immunotherapy of cancer and hold promise as a safe means of enhancing this approach within the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Guidelines for the Safe Administration of High-Dose Interleukin-2
Schwartzentruber, D. J. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200107000-00004 · Cited by 182 · cited 1×
“morbidity associated with high-dose IL-2 delivery and immunodepletion [8].”
Background
Cited by
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
Neuropilin 1: function and therapeutic potential in cancer
Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1500-0 · Cited by 233
“Stimulation of TLR7 and TLR9 has also been shown to be effective in countering anti-tumour immunity and inducing tumour reduction; TLR agonists are currently being tested for their efficacy in cancer therapies and as adjuvants to enhance adoptive T cell therapies [132].”
BackgroundOncolytic virus-derived type I interferon restricts CAR T cell therapy
Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128
Upadhya, S., Andrade, M. J., Shukla, V., Rao, R., & Satyamoorthy, K. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103841 · Cited by 27
Metadata
- Authors
- Amos, S. M., Pegram, H. J., Westwood, J. A., John, L. B., Devaud, C., Clarke, C. J., Restifo, N. P., Smyth, M. J., Darcy, P. K., & Kershaw, M. H.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2011-02-16
- Volume
- 60
- Issue
- 5
- Pages
- 671-683
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2106776403
- Cited by
- 88
- References
- 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. https://app.cochat.ai/papers/10.1007/s00262-011-0984-8
- The paper
- Amos, S. M., Pegram, H. J., Westwood, J. A., John, L. B., Devaud, C., Clarke, C. J., Restifo, N. P., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2011). Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-011-0984-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.